

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
July 14, 2020

**DRAFT MEETING ROSTER**

---

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Yvette Waples, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Massimo Cristofanilli, MD, FACP**

Associate Director of Translational Research and  
Precision Medicine  
Robert H. Lurie Comprehensive Cancer Center  
Chicago, Illinois

**Jorge A. Garcia, MD, FACP**

Chair, Division of Solid Tumor Oncology  
George and Edith Richman Distinguished Scientist  
Chair  
Director, GU Oncology Program  
University Hospitals Seidman Cancer Center  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Susan Halabi, PhD**

Professor of Biostatistics and Bioinformatics  
Duke University Medical Center  
Durham, North Carolina

**Christian S. Hinrichs, MD**

Investigator & Lasker Clinical Research Scholar  
Experimental Transplantation and Immunology  
Branch  
National Cancer Institute (NCI)  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Philip Hoffman, MD**

*(Chairperson)*  
Professor of Medicine  
The University of Chicago  
Section of Hematology/Oncology  
Department of Medicine  
Chicago, Illinois

**David Mitchell**

*(Consumer Representative)*  
Founder, Patients for Affordable Drugs  
Bethesda, Maryland

**Anthony D. Sung, MD**

Assistant Professor of Medicine  
Duke University School of Medicine  
Duke Adult Blood and Marrow Transplant Clinic  
Durham, North Carolina

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
July 14, 2020

**DRAFT MEETING ROSTER (cont.)**

---

---

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Jonathan D. Cheng, MD**

*(Industry Representative)*

Vice President and Oncology Therapeutic Area  
Head, Merck Research Laboratories, Oncology  
Clinical Research  
North Wales, Pennsylvania

**TEMPORARY MEMBERS (Voting)**

**James Chodosh, MD, MPH**

Edith Ives Cogan Professor of Ophthalmology  
Massachusetts Eye and Ear  
Harvard Medical School  
Boston, Massachusetts

**John DeFlice, MD**

*(Patient Representative)*  
Albuquerque, New Mexico

**Brad H. Feldman, MD**

Assistant Professor of Ophthalmology  
Wills Eye Hospital and Thomas Jefferson University  
Philadelphia, Pennsylvania

**Heidi D. Klepin, MD, MS**

Professor of Internal Medicine  
Section of Hematology and Oncology  
Wake Forest University Health Sciences  
Winston Salem, North Carolina

**Grzegorz S. Nowakowski, MD**

Assistant Professor of Medicine  
Mayo Clinic Rochester  
Rochester, Minnesota

**Gita Thanarajasingam, MD**

Consultant, Division of Hematology  
Assistant Professor of Medicine  
Mayo Clinic  
Rochester, Minnesota

**Thomas S. Uldrick, MD, MS**

Deputy Head, Global Oncology  
Associate Member, Vaccine and Infectious Disease  
and Clinical Research Divisions  
Fred Hutchinson Cancer Research Center  
Associate Professor of Medicine  
University of Washington  
Seattle, Washington

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
July 14, 2020

**DRAFT MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Acting Director, Office of Oncologic Disease (OOD)  
Office of New Drugs (OND), CDER, FDA

**Nicole Gormley, MD**

Director (Acting)  
Division of Hematologic Malignancies 2 (DHM2)  
OOD, OND, CDER, FDA

**Bindu Kanapuru, MD**

Multiple Myeloma Team Lead (Acting)  
DHM2, OOD, OND, CDER, FDA

**Andrea Baines, MD, PhD**

Clinical Reviewer  
DHM2, OOD, OND, CDER, FDA

**Wiley Chambers, MD**

Director (Acting)  
Division of Ophthalmology  
Office of Specialty Medicine  
OND, CDER, FDA